New pill AND019 takes on tough breast cancer in first human test

NCT ID NCT05187832

Recruiting now Disease control Sponsor: Kind Pharmaceuticals LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new oral drug called AND019 in 61 postmenopausal women with advanced or metastatic ER+/HER2- breast cancer who have not responded to standard treatments. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. It is a first-in-human study, so results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AND019 (oral capsule)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced ER+/HER2- breast cancer who have run out of standard therapies.
What could go wrong: This is a very early (Phase 1) and small (61 people) trial focused on safety, so it is far from proving effectiveness. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC BREAST CANCER

Contacts and locations

Locations

Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.